Long-term Efficacy, Safety, and Immunogenicity of the Infliximab (IFX) Biosimilar, PF-06438179/GP1111, in Patients with Rheumatoid Arthritis After Switching from Reference IFX or Continuing Biosimilar Therapy: Week 54–78 Data From a Randomized, Double-Blind, Phase III Trial
Cohen, Stanley B., Radominski, Sebastiao C., Kameda, Hideto, Kivitz, Alan J., Tee, Michael, Cronenberger, Carol, Zhang, Min, Hackley, Sarah, Rehman, Muhammad I., von Richter, Oliver, Alten, RiekeLanguage:
english
Journal:
BioDrugs
DOI:
10.1007/s40259-019-00403-z
Date:
January, 2020
File:
PDF, 854 KB
english, 2020